Study guide
14.1 Abnormal Uterine Bleeding & Uterine Fibroids
Combined Medical Services Examination UPSC CMS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Logistics & Pattern
1.1 UPSC CMS Examination Overview & Eligibility 1.2 Two-Paper Written Exam Pattern & Negative Marking 1.3 Personality Test, Service Allocation & Career Paths
2 Chapter 2: General Medicine - Cardiology & Respiratory
2.1 Coronary Artery Disease & Acute Myocardial Infarction 2.2 Heart Failure & Cardiac Arrhythmias 2.3 Community-Acquired Pneumonia & Pulmonary Tuberculosis 2.4 COPD, Bronchial Asthma & Pulmonary Embolism
3 Chapter 3: General Medicine - Gastroenterology & Hepatology
3.1 Peptic Ulcer Disease & Upper GI Bleeding 3.2 Liver Cirrhosis & Portal Hypertension 3.3 Acute & Chronic Viral Hepatitis & Pancreatitis 3.4 Inflammatory Bowel Disease & Malabsorption Syndromes
4 Chapter 4: General Medicine - Nephrology & Endocrinology
4.1 Acute Kidney Injury & Chronic Kidney Disease 4.2 Glomerulonephritis, Nephrotic Syndrome & Electrolyte Imbalances 4.3 Diabetes Mellitus: Diagnosis, Complications & Management 4.4 Thyroid Disorders & Adrenal Gland Dysfunction
5 Chapter 5: General Medicine - Neurology, Haematology & Infection
5.1 Cerebrovascular Accidents (Stroke) & Epilepsy 5.2 Approach to Anaemia: Microcytic, Megaloblastic & Haemolytic 5.3 Acute & Chronic Leukaemias and Lymphomas 5.4 Tropical & Endemic Infections: Malaria, Typhoid & Dengue
6 Chapter 6: General Medicine - Emergency Medicine & Toxicology
6.1 Acute Anaphylaxis, Sepsis & Cardiopulmonary Resuscitation 6.2 Organophosphate, Paracetamol & Snakebite Toxicology 6.3 Common Dermatological & Psychiatric Manifestations in Internal Medicine 6.4 Musculoskeletal System & Adult Rheumatology
7 Chapter 7: Paediatrics - Neonatology & Child Growth
7.1 Newborn Care, Neonatal Resuscitation & APGAR Score 7.2 Prematurity, Low Birth Weight & Neonatal Jaundice 7.3 Infant & Child Growth & Developmental Milestones
8 Chapter 8: Paediatrics - Child Health & Nutrition
8.1 Protein-Energy Malnutrition (PEM) & Micronutrient Deficiencies 8.2 Universal Immunization Programme (UIP) & Child Vaccines 8.3 Pediatric Diarrhoea, Dehydration & Respiratory Emergencies 8.4 Birth Defects, Genetic Counseling, Autism & Paediatric Accidents/Poisoning
9 Chapter 9: Surgery - General Surgery, Wounds & Shock
9.1 Wound Healing, Surgical Site Infections & Gas Gangrene 9.2 Pathophysiology of Shock & Perioperative Fluid Therapy 9.3 Acute Abdomen: Appendicitis, Peritonitis & Intestinal Obstruction 9.4 Classification, Resuscitation & Management of Thermal Burns 9.5 Medicolegal & Ethical Issues in Surgery
10 Chapter 10: Surgery - Surgical Specialties I
10.1 Inguinal, Femoral & Ventral Hernias 10.2 Benign Breast Diseases & Breast Carcinoma 10.3 Solitary Thyroid Nodule & Thyroid Carcinoma 10.4 Benign Prostatic Hyperplasia & Renal Calculi
11 Chapter 11: Surgery - ENT, Orthopaedics & Anaesthesia
11.1 Acute Otitis Media, Tonsillitis & Epistaxis 11.2 Cataract, Glaucoma & Red Eye Emergencies 11.3 Principles of Fracture Management & Common Dislocation 11.4 Principles of Local, Regional & General Anaesthesia 11.5 Neurosurgery: Raised ICP, Head Injury & CNS Lesions 11.6 Thoracic Surgery: Chest Trauma, Pleural & Lung Disease
12 Chapter 12: Obstetrics - Antenatal Care & Complications
12.1 Antenatal Care, Maternal Nutrition & Fetal Assessment 12.2 Preeclampsia, Eclampsia & Gestational Hypertension 12.3 Antepartum Haemorrhage: Placenta Previa & Abruptio Placentae 12.4 Anemia in Pregnancy & Gestational Diabetes Mellitus 12.5 Spontaneous & Recurrent Abortion: Recognition & Management
13 Chapter 13: Obstetrics & Gynaecology - Labor & PPH
13.1 Normal Labor Mechanisms & Partograph Monitoring 13.2 Malpresentations, Breech & Obstructed Labor 13.3 Postpartum Haemorrhage (PPH) Causes & Management 13.4 Puerperal Sepsis & Postnatal Maternal Care
14 Chapter 14: Gynaecology & Family Planning
14.1 Abnormal Uterine Bleeding & Uterine Fibroids 14.2 Cervical Screening (Pap Smear) & Pelvic Inflammatory Disease 14.3 Temporary & Permanent Contraceptive Methods in India 14.4 Medical Termination of Pregnancy (MTP): Law & Methods
15 Chapter 15: PSM - Epidemiology & Biostatistics
15.1 Principles of Epidemiology & Disease Transmission 15.2 Observational & Experimental Epidemiological Study Designs 15.3 Evaluation of Screening Tests: Sensitivity, Specificity & Predictive Value 15.4 Biostatistics: Sampling, Central Tendency & Significance Testing
16 Chapter 16: PSM - Disease Epidemiology & Programmes
16.1 Epidemiology & Control of TB, Malaria & Dengue 16.2 National Tuberculosis Elimination Programme & NVBDCP 16.3 Epidemiology of Hypertension, Diabetes & Cancer in India 16.4 Cold Chain Management & Vaccine Logistics in India 16.5 Genetics and Health: Inheritance, Screening & Counseling
17 Chapter 17: PSM - Health Planning & Environmental Health
17.1 Demography, Fertility Rates & Family Welfare Indicators 17.2 Safe Water Supply, Waste Disposal & Air Pollution 17.3 Occupational Health Hazards & Pneumoconioses 17.4 Health Care Delivery System, Ayushman Bharat & National Health Mission 17.5 International Health: WHO, Global Agencies & SDG 3 17.6 Medical Sociology & Health Education
14.1 Abnormal Uterine Bleeding & Uterine Fibroids
Key Takeaways Explain This Topic AI
The FIGO PALM-COEIN classification system categorizes abnormal uterine bleeding into structural causes (Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not otherwise classified).
Uterine leiomyomas (fibroids) are estrogen- and progesterone-dependent benign smooth muscle tumors classified by FIGO sub-location from Type 0 (pedunculated submucosal) to Type 8 (other, e.g. cervical or broad ligament).
Red (carneous) degeneration occurs predominantly during pregnancy due to rapid fibroid growth outstripping blood supply leading to aseptic necrobiosis; it presents with localized pain, fever, and leukocytosis, and is managed conservatively with analgesics.
First-line medical therapy for AUB-L includes antifibrinolytics (Tranexamic acid) and NSAIDs during menses, while the Levonorgestrel Intrauterine System (LNG-IUS) is the gold standard medical intervention for heavy menstrual bleeding.
Surgical intervention is dictated by fertility goals: hysteroscopic myomectomy for submucosal fibroids, laparoscopic/abdominal myomectomy for intramural/subserosal fibroids in women desiring fertility, and hysterectomy as definitive treatment.
Last updated: July 2026
14.1 Abnormal Uterine Bleeding & Uterine Fibroids
Abnormal Uterine Bleeding (AUB) is one of the most common presenting complaints in gynaecological practice, accounting for over 30% of outpatient consultations in women of reproductive age. A thorough understanding of its classification, underlying structural abnormalities—specifically uterine leiomyomas—and evidence-based management protocols is essential for the UPSC Combined Medical Services (CMS) examination.
PALM-COEIN Classification System (FIGO 2011/2018)
To standardize terminology and clinical evaluation, the International Federation of Gynecology and Obstetrics (FIGO) established the PALM-COEIN classification system. This system divides AUB in non-pregnant women of reproductive age into nine discrete categories, stratified into structural causes (visualized via imaging or histopathology) and non-structural causes.
Classification Category Key Clinical Features & Diagnostic Modalities
P Polyp (AUB-P) Benign endometrial or cervical epithelial growths; diagnosed via Transvaginal Sonography (TVS), Saline Infusion Sonohysterography (SIS), or Hysteroscopy.
A Adenomyosis (AUB-A) Presence of heterotopic endometrial glands and stroma within the myometrium with adjacent myometrial hypertrophy; presents with globular enlarged tender uterus, severe dysmenorrhea, and menorrhagia.
L Leiomyoma (AUB-L) Benign smooth muscle tumors; sub-classified into submucosal ( AUB-L sm \text{AUB-L}_{\text{sm}} AUB-L sm ) and other ( AUB-L o \text{AUB-L}_{\text{o}} AUB-L o ).
M Malignancy & Hyperplasia (AUB-M) Endometrial hyperplasia (with or without atypia) and endometrial carcinoma or leiomyosarcoma; suspected in postmenopausal bleeding or persistent AUB with endometrial thickness >4 mm postmenopause or >12 mm in premenopause.
C Coagulopathy (AUB-C) Systemic disorders of hemostasis; von Willebrand disease is the most common inherited cause (~13% of women with unexplained heavy menstrual bleeding).
O Ovulatory Dysfunction (AUB-O) Anovulatory bleeding caused by Polycystic Ovary Syndrome (PCOS), hypothyroidism, hyperprolactinemia, eating disorders, or perimenopause; presents as irregular, unpredictable, painless heavy bleeding.
E Endometrial (AUB-E) Primary endometrial dysfunction involving impaired local vasoconstriction (reduced endothelin-1, elevated PGE2/PGI2) or excessive local fibrinolysis; presents with predictable, cyclic heavy bleeding in regular ovulatory cycles.
I Iatrogenic (AUB-I) Bleeding secondary to medications or devices: Copper-T IUDs, progestin-only contraceptives, systemic anticoagulants, psychotropics affecting prolactin, or tamoxifen.
N Not Otherwise Classified (AUB-N) Rare or poorly defined conditions (e.g., arteriovenous malformations, myometrial hypertrophy).
Clinical Pearl for UPSC CMS: Heavy Menstrual Bleeding (HMB) is defined objectively as menstrual blood loss >80 mL per cycle or bleeding lasting >7 days. Subjectively, it is any excessive menstrual blood loss that interferes with a woman's physical, emotional, social, and material quality of life.
Uterine Leiomyomas (Fibroids)
Uterine leiomyomas are benign, monoclonal, estrogen- and progesterone-dependent smooth muscle tumors originating from myometrial smooth muscle cells and surrounding extracellular matrix. They occur in up to 70–80% of women by age 50 and represent the single most common indication for hysterectomy worldwide.
Risk & Protective Factors
Risk Factors: Nulliparity, early menarche (<10 years), obesity (increased peripheral aromatization of androgens to estrogens in adipose tissue), African ethnicity, positive family history (first-degree relative), and polycystic ovary syndrome.
Protective Factors: Multiparity, increased duration of lactation, combined oral contraceptive pill use, and smoking (induces hepatic hypoestrogenism via cytochrome P450 activation).
FIGO Subclassification System for Leiomyomas (Types 0 to 8)
FIGO categorizes leiomyomas based on their exact anatomical relation to the endometrium and serosa: FIGO Classification Table:
- Type 0: Pedunculated intracavitary submucosal
- Type 1: Submucosal, <50% intramural
- Type 2: Submucosal, ≥50% intramural
- Type 3: 100% Intramural, contacts endometrium
- Type 4: 100% Intramural, no contact with endometrium/serosa
- Type 5: Subserosal, ≥50% intramural
- Type 6: Subserosal, <50% intramural
- Type 7: Pedunculated subserosal
- Type 8: Other (cervical, broad ligament, parasitic)
- Hbrid: Two numbers (e.g., 2-5) indicating submucosal and subserosal extent
- Secondary Degenerations of Fibroids
As fibroids outgrow their blood supply (derived primarily from peripheral arcade vessels), secondary degenerative changes occur:
Hyaline Degeneration (60–65%): The most common degeneration; smooth muscle tissue is replaced by homogeneous pink, acellular hyaline tissue.
Cystic Degeneration (4%): Hyaline tissue liquefies to form fluid-filled cystic cavities; frequently follows hyaline degeneration.
Calcific / Calcareous Degeneration (10%): Deposition of calcium carbonate and phosphate, typically in postmenopausal women secondary to circulatory failure; visible as a 'womb stone' on pelvic X-ray.
Red (Carneous) Degeneration: Aseptic necrobiosis occurring characteristically during the second trimester of pregnancy or early puerperium. Rapid estrogen-driven enlargement outstrips blood supply, causing venous thrombosis and hemorrhagic infarction. Presenting features include acute focal abdominal pain, localized uterine tenderness over the fibroid, low-grade fever, leukocytosis, and elevated ESR. Management is strictly conservative with bed rest, hydration, and analgesics (Paracetamol / short-course NSAIDs before 32 weeks).
Myxoid Degeneration: Soft gelatinous material within the tumor.
Malignant Transformation (Leiomyosarcoma): Occurs in <0.1% of fibroids; suspected when a rapid growth occurs in postmenopausal women.
Diagnostic Workup
Bimanual Pelvic Examination: Reveals an enlarged, firm, irregularly contoured, non-tender, mobile uterus (unless fixed by adhesions or broad ligament fibroids).
Transvaginal Ultrasonography (TVS): First-line imaging modality. Demonstrates well-defined, hypoechoic, heterogeneous myometrial masses with acoustic shadowing.
Saline Infusion Sonohysterography (SIS) / Hysteroscopy: Gold standard for evaluating submucosal cavity distortion (Types 0, 1, and 2).
Magnetic Resonance Imaging (MRI): Most precise imaging modality for mapping exact fibroid count, size, and FIGO location prior to planned myomectomy or Uterine Artery Embolization.
- Evidence-Based Management Protocols
- 1. Medical Management
Indicated for symptom control in mild-to-moderate AUB-L, preoperatively to shrink fibroids and correct anemia, or in women nearing menopause.
Tranexamic Acid: Antifibrinolytic that competitively inhibits plasminogen activation. Administered at 1 g orally TID during active menses; reduces menstrual blood loss by 40–50% without altering fibroid volume.
NSAIDs (Mefenamic acid 500 mg TID): Inhibits cyclooxygenase, reducing endometrial prostaglandin (PGE2/PGF2α) synthesis. Reduces blood loss by 20–30% and alleviates dysmenorrhea.
Levonorgestrel Intrauterine System (LNG-IUS / Mirena 52 mg): Releases 20 mcg LNG daily directly into the endometrial cavity. Induces profound endometrial atrophy. Gold standard medical management for AUB-L when no cavity distortion (FIGO Types 3–8) is present, reducing blood loss by >90% at 12 months.
GnRH Agonists (Leuprolide acetate 3.75 mg monthly IM / Goserelin 3.6 mg SC): Binds to pituitary GnRH receptors, causing initial flare followed by receptor downregulation and profound hypoestrogenism. Reduces fibroid volume by 40–60% within 3 months and induces amenorrhea. Limited to 3–6 months preoperatively due to bone mineral density (BMD) loss and vasomotor symptoms (unless add-back hormone therapy is co-administered).
Selective Progesterone Receptor Modulators (SPRMs - Ulipristal Acetate 5 mg daily): Inhibits progesterone-driven fibroid cell proliferation and induces apoptosis without severe hypoestrogenism. Used as short-term preoperative therapy.
2. Surgical & Interventional Management
Uterine Artery Embolization (UAE / UFE): Interventional radiologic procedure where polyvinyl alcohol (PVA) microspheres are injected into bilateral uterine arteries via femoral artery access. Leads to ischemic necrosis and infarction of fibroids with ~50% volume reduction. Absolute Contraindication: Active pelvic infection, pregnancy, suspected malignancy, and women desiring future fertility (due to risk of ovarian failure and impaired placentation).
Myomectomy: Surgical excision of fibroids preserving the uterus. Indicated for women desiring future childbearing or organ preservation.
Hysteroscopic Myomectomy: Choice for FIGO Type 0 and Type 1 submucosal fibroids <4 cm.
Laparoscopic / Abdominal Myomectomy: Indicated for intramural (Types 3, 4) and subserosal (Types 5, 6, 7) fibroids. Note: Enteric opening of the endometrial cavity during myomectomy mandates planned elective Cesarean section at term in subsequent pregnancies to prevent uterine rupture.
Hysterectomy: Total or subtotal abdominal, laparoscopic, or vaginal hysterectomy. The definitive cure for AUB-L in women who have completed childbearing.